Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05060432 · ClinicalTrials.gov registry record · Phase 1
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
A Phase 1 study of Lung Cancer and Melanoma, sponsored by iTeos Belgium.
- Active
- Registry status
- Phase 1
- Development phase
- 153
- Enrollment target
- 20
- Study locations
NCT05060432: Active Phase 1 study of Lung Cancer and Melanoma, sponsored by iTeos Belgium.
NCT05060432 is a Phase 1 study of Lung Cancer and Melanoma that is active but no longer recruiting, run by iTeos Belgium. The registered enrollment target is 153 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05060432, a Phase 1 study of Lung Cancer and Melanoma, is active but no longer recruiting, sponsored by iTeos Belgium.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 153 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG Dostarlimab
- DRUG inupadenant
- DRUG EOS-448
- DRUG SOC chemotherapies
Study Locations (20)
Other
- Cliniques universitaires St Luc-UCL - Brussels
- Jessa Ziekenhuis - Hasselt
- UZ Leuven - Leuven
- CHU Helora - Mons
- Hôpital Saint André - Bordeaux
- CHU Caen - Caen
- Centre Georges Francois Leclerc - Dijon
- Clinique Victor Hugo - Le Mans
- Centre Oscar Lambret - Lille
- Centre Léon Bérard - Lyon
- Institut de Cancerologie Lorraine (ICL) - Nancy
- Institut de Cancérologie de l'Ouest - Nantes
- Centre Antoine Lacassagne - Nice
- Pitié Salpêtrière - Paris
- CHU de POITIERS - Poitiers
- ICANS - Strasbourg
California
- University of California San Diego - San Diego
New Jersey
- Hackensack University Medical Center - Bergen
Antwerp
- GZA Ziekenhuizen campus Sint-Augustinus - Antwerp
Milan
- IDB Center-Istituto Clinico Humanitas (IRCCS) - Rozzano
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2021-09-06 |
| Est. Completion | 2025-07 |
| Phase | Phase 1 |
What the registry record for NCT05060432 still lists
NCT05060432 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (84% lower).
The record links to 4 conditions, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which pembrolizumab is the first listed.
NCT05060432 names 20 study sites across 5 states, led by Other, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05060432 about?
NCT05060432 is a clinical study titled "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors". This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants ...
What is the current status of trial NCT05060432?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2021-09-06. Estimated completion is 2025-07.
What conditions does trial NCT05060432 study?
This clinical trial studies the following conditions: Lung Cancer, Melanoma, Head and Neck Cancer, Advanced Cancer.
What interventions are being tested in trial NCT05060432?
The interventions under investigation include: pembrolizumab (DRUG), Dostarlimab (DRUG), inupadenant (DRUG), EOS-448 (DRUG), SOC chemotherapies (DRUG).
Who is sponsoring clinical trial NCT05060432?
This trial is sponsored by iTeos Belgium, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05060432 being conducted?
This trial has 20 study locations across California, New Jersey, Antwerp, Milan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05060432's enrollment target sits among peer trials
153 146th of 409 higher than 264 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI